The safety of using anti-VEGF: Is there strength in numbers? Curtis LH, Hammill BG, Schulman KA, Cousins SW (2010) Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 128(10):1273-1279

Graefes Arch Clin Exp Ophthalmol. 2011 Feb;249(2):161-2. doi: 10.1007/s00417-010-1603-7. Epub 2011 Jan 6.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Angiogenesis Inhibitors / administration & dosage
  • Angiogenesis Inhibitors / adverse effects*
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal, Humanized
  • Aptamers, Nucleotide / administration & dosage
  • Aptamers, Nucleotide / adverse effects
  • Bevacizumab
  • Cause of Death
  • Hemorrhage / etiology
  • Hemorrhage / mortality*
  • Humans
  • Macular Degeneration / drug therapy*
  • Myocardial Infarction / etiology
  • Myocardial Infarction / mortality*
  • Photochemotherapy / adverse effects
  • Ranibizumab
  • Risk Factors
  • Stroke / etiology
  • Stroke / mortality*
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors*

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Aptamers, Nucleotide
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • pegaptanib
  • Bevacizumab
  • Ranibizumab